Calithera Biosciences, Inc. (NASDAQ:CALA) Q2 2020 Earnings Conference Call - Final Transcript

Aug 10, 2020 • 05:00 pm ET


Calithera Biosciences, Inc. (NASDAQ:CALA) Q2 2020 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Ladies and gentlemen, thank you for standing by, and welcome to the Calithera Second Quarter Earnings Call.

[Operator Instructions] I would now like to hand the conference over to your speaker, Jennifer McNealey. Please go ahead.

Jennifer McNealey

Thank you, Sydney. Good afternoon, everyone. Welcome to our second quarter 2020 conference call. Joining me today are Susan Molineaux, our Founder, President and CEO; Keith Orford, Chief Medical Officer; and Stephanie Wong, SVP of Finance. We have issued our press release and it could be accessed through our website at

Before we begin, I would like to remind you that today's discussion will include statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Security Litigations Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those in the risk factors discussed in the Risk Factors section of our quarterly report on Form 10-Q filed with the SEC.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change. Please note that this call is being recorded.

And with that, I'll turn the call over to Susan.

Susan M. Molineaux

Thanks, Jennifer, and good afternoon, everyone. Thank you for joining us today on our second quarter 2020 conference call. On behalf of the entire team, I'd like to say we hope that you and your families remain healthy while the world addresses the challenges of the COVID-19 pandemic. After a number of months working from home, we can say that we have transitioned smoothly to the new work environment and are prepared to maintain this work schedule into the coming months.

At the same time, we have reopened our labs and have been able to maintain a safe environment for those workers who have returned to the office. We want to thank all of our employees who have done an extraordinary job of maintaining a high level of professionalism, productivity, and dedication at work, while balancing it with all the personal challenges that COVID-19 brings. We're both appreciative and proud of our entire team.

We continued our positive momentum from 2019 into the first half of 2020, further strengthening our cash position and advancing our key clinical development programs. At Calithera, we're building an integrated biotechnology company that develops novel, small molecule, oncometabolism drugs. Drugs that are targeting tumor and immune cell metabolism pathways for the treatment of cancer and other diseases.

By building a pipeline of novel therapeutic product candidates, we're creating multiple opportunities to positively impact clinical outcomes for patients and drive development programs towards commercialization. We're the first company to take a selective glutaminase inhibitor into the clinic and the first to demonstrate